Drug Type Small molecule drug |
Synonyms NBT 287, NBT-287, TPI 287 + [1] |
Target |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC46H63NO15 |
InChIKeyFDTAUJJRHBRHIJ-FDJAAIFISA-N |
CAS Registry849213-15-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Glioblastoma | Phase 2 | US | 01 Jan 2014 | |
Metastatic melanoma | Phase 2 | US | 01 Sep 2013 | |
Refractory Neuroblastoma | Phase 2 | US | 01 Dec 2011 | |
Medulloblastoma | Phase 2 | US | 01 Dec 2011 | |
Breast Cancer | Phase 2 | US | 16 Aug 2011 | |
Breast Carcinoma Metastatic in the Brain | Phase 2 | US | 16 Aug 2011 | |
Glioblastoma Multiforme | Phase 2 | US | 01 Apr 2010 | |
Pancreatic carcinoma non-resectable | Phase 2 | US | 01 Oct 2007 | |
Pancreatic carcinoma non-resectable | Phase 2 | ES | 01 Oct 2007 | |
Prostatic cancer metastatic | Phase 2 | US | 01 Jan 2007 |
Phase 1 | 68 | oeqifmmncy(mukqblmkdo) = bkctcnvoys ynokrxdxcj (svsoosqkzy ) View more | Positive | 01 Feb 2020 | |||
Placebo | oeqifmmncy(mukqblmkdo) = vxwnfdyiyy ynokrxdxcj (svsoosqkzy ) View more | ||||||
Phase 1/2 | 12 | TPI+Bevacizumab (TPI 287 160 mg/m2 + Bevacizumab) | szkyhxnvgy(mbjecaxidu) = hlnzfqozav oijnuiexud (gdnurizpti, iqoqkveqkc - xedjhwyjhr) View more | - | 05 Jun 2019 | ||
TPI+Bevacizumab (TPI 287 140 mg/m2 + Bevacizumab) | szkyhxnvgy(mbjecaxidu) = ipgimiedhy oijnuiexud (gdnurizpti, fhuaxolskl - apeoxvyumh) View more | ||||||
Phase 2 | 24 | azrzykxghb(sdvsoksgmj) = fjzuwabuzr gygzzxzhlh (nrdjbztsuk, fkzhcjnopw - ddqblllnau) View more | - | 10 Jul 2018 | |||
NCT01933815 (ASCO2017) Manual | Phase 1/2 | 24 | whaxypsytd(hnykajgkgz) = eyvaywnlfc hnyktrzfva (vcifpgydxs ) View more | Positive | 05 Jun 2017 | ||
Phase 1 | 21 | dioqvljbpt(zrkimkghne) = neuropathy and six patients experienced grade III neuropathy xuwbbhxkim (pjrrfqulhn ) View more | Positive | 01 Dec 2016 | |||
Phase 2 | 17 | qefgnzxyna(hncmpfpahq) = mgcbfndphw zktvswpgnb (ombprzkirw, fpzkpkshff - opxtgtwoxh) View more | - | 31 Oct 2016 | |||
Phase 1/2 | - | 14 | (Arm A- Temozolomide and Irinotecan) | ckdlfblyxr(bndobjlper) = llskpggmdv tngjmttyce (fnqtrvverv, sspxglilth - iuggattrnu) View more | - | 28 Oct 2016 | |
(Arm B- Temozolomide/Irinotecan + TPI 287) | vqqbvllqly(azpyhevrpp) = jioezjtghb egrhtcftjc (ctmovicjfk, vjhgxenrzm - nartmgffta) | ||||||
Phase 1/2 | 8 | ddgxriptyx(uqlrbhrtdg) = pkgmvfubce upsytewziy (hycohgheqf, qlysbcpnkk - czsyqpajsz) View more | - | 28 Oct 2016 | |||
Phase 1 | 18 | zvslpdmdhp(uzwpdtlcin) = edrecnqfdb spnsyzhlph (jejtrdalpx, nfnbrmzigd - ulxepysgvu) View more | - | 28 Oct 2016 | |||
Phase 1 | 36 | ymfjpgvndo(zrjjpehjlc) = zbehlieijp wbjipqffxv (kysdzdhhmc ) | - | 20 May 2015 | |||
(FSRT) | ymfjpgvndo(zrjjpehjlc) = ckwumnwhkq wbjipqffxv (kysdzdhhmc ) |